17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 118 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112

  
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-014644-11-AT
(EUCTR)
10/03/201021/10/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Austria;Italy;Spain;France;Netherlands;Germany;United Kingdom;Hungary;Portugal
2EUCTR2009-014644-11-NL
(EUCTR)
11/02/201029/10/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
243Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
3EUCTR2009-014644-11-PT
(EUCTR)
05/02/201011/01/2010A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Hungary;Portugal;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
4EUCTR2009-014644-11-GB
(EUCTR)
25/01/201004/08/2010A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noPortugal;France;Hungary;Spain;Austria;Netherlands;Germany;Italy;United Kingdom
5EUCTR2009-014644-11-IT
(EUCTR)
10/12/200922/12/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - NDA Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - ND Multiple System Atrophy of the Parkinsonian subtype (MSA-P)
MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
6EUCTR2009-014644-11-DE
(EUCTR)
08/12/200915/09/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
7NCT00977665
(ClinicalTrials.gov)
December 200915/9/2009Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)Multiple System AtrophyDrug: rasagiline mesylate;Drug: placeboTeva Pharmaceutical IndustriesH. Lundbeck A/SCompleted30 YearsN/AAll174Phase 2United States;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Spain;United Kingdom
8EUCTR2009-014644-11-FR
(EUCTR)
17/11/200922/09/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noPortugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
9EUCTR2009-014644-11-ES
(EUCTR)
22/10/200924/09/2009 A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) Pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P)
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT 1 mg comprimidos
INN or Proposed INN: RASAGILINA MESILATO
Other descriptive name: RASAGILINA MESILATO
Teva Pharmaceutical Industries LtdNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noPortugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
10EUCTR2009-014644-11-HU
(EUCTR)
19/10/200925/09/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria